Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Open-label, Multicenter Dose Escalation and Expansion Study of MT-5111 in Subjects With Previously Treated Advanced HER2-positive Solid Tumors

Next Previous
Trial Profile

A Phase 1 Open-label, Multicenter Dose Escalation and Expansion Study of MT-5111 in Subjects With Previously Treated Advanced HER2-positive Solid Tumors

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 20 Jun 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs MT 5111 (Primary)
  • Indications Adenocarcinoma; Advanced breast cancer; Biliary cancer; Cholangiocarcinoma; Colon cancer; Colorectal cancer; Gallbladder cancer; Gastric cancer; Gastrointestinal cancer; HER2 positive breast cancer; Lung cancer; Oesophageal cancer; Pancreatic cancer; Rectal cancer; Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Molecular Templates

Most Recent Events

  • 15 Jun 2023 Status changed from recruiting to discontinued.
  • 10 Dec 2022 Interim Results (As of 30 June 2022, n=42 ) presented at the 45th Annual San Antonio Breast Cancer Symposium
  • 02 Dec 2022 According to a Molecular Templates media release, interim data from this study will be presented at the 45th Annual San Antonio Breast Cancer Symposium (SABCS).

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top